213 related articles for article (PubMed ID: 28792244)
1. A novel α
Wang F; Li L; Sun W; Li L; Liu Y; Huang Y; Zhou Z
J Drug Target; 2018 Mar; 26(3):231-241. PubMed ID: 28792244
[TBL] [Abstract][Full Text] [Related]
2. Synergistic enhancement of anticancer therapeutic efficacy of HPMA copolymer doxorubicin conjugates via combination of ligand modification and stimuli-response srategies.
Li L; Zhou M; Huang Y
Int J Pharm; 2018 Jan; 536(1):450-458. PubMed ID: 29237570
[TBL] [Abstract][Full Text] [Related]
3. Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells.
David A; Kopecková P; Minko T; Rubinstein A; Kopecek J
Eur J Cancer; 2004 Jan; 40(1):148-57. PubMed ID: 14687799
[TBL] [Abstract][Full Text] [Related]
4. Assessing the therapeutic efficacy of VEGFR-1-targeted polymer drug conjugates in mouse tumor models.
Shamay Y; Golan M; Tyomkin D; David A
J Control Release; 2016 May; 229():192-199. PubMed ID: 27001892
[TBL] [Abstract][Full Text] [Related]
5. Polymeric drug-carriers containing doxorubicin and melanocyte-stimulating hormone: in vitro and in vivo evaluation against murine melanoma.
O'Hare KB; Duncan R; Strohalm J; Ulbrich K; Kopeckova P
J Drug Target; 1993; 1(3):217-29. PubMed ID: 8069563
[TBL] [Abstract][Full Text] [Related]
6. Peptide-directed HPMA copolymer-doxorubicin conjugates as targeted therapeutics for colorectal cancer.
Kopansky E; Shamay Y; David A
J Drug Target; 2011 Dec; 19(10):933-43. PubMed ID: 22074249
[TBL] [Abstract][Full Text] [Related]
7. Enhanced intracellular and intranuclear drug delivery mediated by biomimetic peptide SVS-1 for anticancer therapy.
Xiang Y; Chen L; Zhou R; Huang Y
Int J Pharm; 2019 Oct; 570():118668. PubMed ID: 31494237
[TBL] [Abstract][Full Text] [Related]
8. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM
J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970
[TBL] [Abstract][Full Text] [Related]
9. The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel.
Šírová M; Strohalm J; Chytil P; Lidický O; Tomala J; Říhová B; Etrych T
J Control Release; 2017 Jan; 246():1-11. PubMed ID: 27940304
[TBL] [Abstract][Full Text] [Related]
10. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy.
Etrych T; Mrkvan T; Ríhová B; Ulbrich K
J Control Release; 2007 Sep; 122(1):31-8. PubMed ID: 17631976
[TBL] [Abstract][Full Text] [Related]
11. Doxorubicin-loaded, charge reversible, folate modified HPMA copolymer conjugates for active cancer cell targeting.
Li L; Yang Q; Zhou Z; Zhong J; Huang Y
Biomaterials; 2014 Jun; 35(19):5171-87. PubMed ID: 24702960
[TBL] [Abstract][Full Text] [Related]
12. Improvement of anti-tumor abilities on human non-small cell lung carcinoma by micellization and cross-linking of N-(2-hydroxypropyl) methacrylamide copolymers.
Zhou Z; Xu X; Li L; Huang Y
J Drug Target; 2015; 23(9):821-31. PubMed ID: 25830626
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of poly[N-(2-hydroxypropyl)methacrylamide] conjugates of inhibitors of the ABC transporter that overcome multidrug resistance in doxorubicin-resistant P388 cells in vitro.
Subr V; Sivák L; Koziolová E; Braunová A; Pechar M; Strohalm J; Kabešová M; Ríhová B; Ulbrich K; Kovář M
Biomacromolecules; 2014 Aug; 15(8):3030-43. PubMed ID: 24978588
[TBL] [Abstract][Full Text] [Related]
14. A pH-responsive cell-penetrating peptide-modified liposomes with active recognizing of integrin αvβ3 for the treatment of melanoma.
Shi K; Li J; Cao Z; Yang P; Qiu Y; Yang B; Wang Y; Long Y; Liu Y; Zhang Q; Qian J; Zhang Z; Gao H; He Q
J Control Release; 2015 Nov; 217():138-50. PubMed ID: 26368312
[TBL] [Abstract][Full Text] [Related]
15. Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting.
Etrych T; Chytil P; Mrkvan T; Sírová M; Ríhová B; Ulbrich K
J Control Release; 2008 Dec; 132(3):184-92. PubMed ID: 18534705
[TBL] [Abstract][Full Text] [Related]
16. The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia.
Tomalova B; Sirova M; Rossmann P; Pola R; Strohalm J; Chytil P; Cerny V; Tomala J; Kabesova M; Rihova B; Ulbrich K; Etrych T; Kovar M
J Control Release; 2016 Feb; 223():1-10. PubMed ID: 26708020
[TBL] [Abstract][Full Text] [Related]
17. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
[TBL] [Abstract][Full Text] [Related]
18. PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination.
Satchi-Fainaro R; Hailu H; Davies JW; Summerford C; Duncan R
Bioconjug Chem; 2003; 14(4):797-804. PubMed ID: 12862433
[TBL] [Abstract][Full Text] [Related]
19. PDEPT: polymer-directed enzyme prodrug therapy. I. HPMA copolymer-cathepsin B and PK1 as a model combination.
Satchi R; Connors TA; Duncan R
Br J Cancer; 2001 Sep; 85(7):1070-6. PubMed ID: 11592781
[TBL] [Abstract][Full Text] [Related]
20. Polymeric nanomedicine for tumor-targeted combination therapy to elicit synergistic genotoxicity against prostate cancer.
Yang Q; Yang Y; Li L; Sun W; Zhu X; Huang Y
ACS Appl Mater Interfaces; 2015 Apr; 7(12):6661-73. PubMed ID: 25775367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
